BLTE: Belite Bio, Inc insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 8 sales totaling $83K in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-01 | Scholl Hendrik Peter | Officer | $33K | yes |
| 2026-10-01 | Scholl Hendrik Peter | Officer | $4K | yes |
| 2026-10-01 | Scholl Hendrik Peter | Officer | $20K | yes |
| 2026-10-01 | Scholl Hendrik Peter | Officer | $8K | yes |
| 2026-10-01 | Scholl Hendrik Peter | Officer | $13K | yes |
| 2026-10-01 | Scholl Hendrik Peter | Officer | $2K | yes |
| 2026-10-01 | Scholl Hendrik Peter | Officer | $2K | yes |
| 2026-10-01 | Scholl Hendrik Peter | Officer | $340 | yes |
Institutional ownership (Q2 2026)
80 institutions reported holding $1.41B of Belite Bio, Inc on Form 13F (75 the quarter before). 21 opened a new position and 16 sold out. Shares held by institutions: +6%.
| Largest holders | Shares | Value |
|---|---|---|
| Darwin Global Management, Ltd. | 3,077,219 | $456.59M |
| Paradigm Biocapital Advisors LP | 1,232,877 | $189.84M |
| RTW INVESTMENTS, LP | 715,332 | $110.15M |
| MILLENNIUM MANAGEMENT LLC | 494,564 | $76.16M |
| MAVERICK CAPITAL LTD | 396,311 | $61.03M |
| EVENTIDE ASSET MANAGEMENT, LLC | 390,829 | $60.18M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 357,199 | $55.00M |
| Holocene Advisors, LP | 251,035 | $38.66M |
| Logos Global Management LP | 250,000 | $38.50M |
| MORGAN STANLEY | 235,071 | $36.20M |
Clinical trial readouts
1 Phase 2 or 3 trials by Belite Bio, Inc with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-06-30 (est.) | Tinlarebant | Geographic Atrophy | Phase 3 | 429 | Enrollment complete | NCT05949593 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.